Dear Colleagues,

Pelvic tumors may involve specific organs in the pelvis or occupy intra-organ spaces. Many different tumors can present a secondary localization in the pelvis, such as ovarian, bladder, rectal, anal, uterine, and prostate tumors, Ewing's sarcoma, teratoma, lipoma, breast, gastric cancer, or carcinosis. Many of these tumors are challenging to treat via diagnostic and therapeutic management and require a multimodal treatment. However, recent advances in imaging and precision medicine are driving advancements in the management of these tumors. Improved staging now allows for better treatment tailoring and more conservative management, such as spread sentinel node assessment in pelvic tumors instead of lymphadenectomy. Additionally, nerve-sparing surgery or conservative management of early gynecological cancers improves patient survival and quality of life. Alongside improved diagnostics, conservative surgery, nanotechnology, and molecular medicine, precision medicine allows for the specific delivery of therapeutic agents, thus improving treatment outcomes and reducing side effects. These developments aspire to improve oncologic outcomes and quality of life while reducing side effects. The present Special Issue focuses on recent advancements in managing the diagnosis and treatment of pelvic tumors.

We are pleased to invite you to contribute to this Special Issue, "Advances in the Diagnosis and Treatment of Pelvic Tumor," which aims to enhance the existing literature in this rapidly growing field with an overview of the advances in the diagnosis and treatment of pelvic tumors. Papers detailing advanced diagnostic technology alongside precision medicine aiming at improving diagnosis, treatment effects, and reducing side effects are sought.

Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

• Advancements in ultrasonography technics: 2D/3D pelvic ultrasound imaging, 3D/PD pelvic ultrasound imaging and elastography in pelvic tumor diagnosis and staging;
• Ultrasound-based models and fusion imaging of ultrasounds and MRI, CT, and PET in staging pelvic tumors;
• Application of contrast-enhanced sonographic medium CEUS in early diagnosis of pelvic tumors;
• Drug targeting and nanotechnology and integration with individualized therapy (i.e., novel therapeutics: genetic-based, nanotechnology, and targeting strategies).

Dr. Anjeza Xholli
Dr. Ambrogio P. Londero
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ultrasonography
• imaging diagnosis and staging
• pelvic tumor
• biomarker for pelvic tumors
• pharmacogenomics
• nanotechnology
• treatment of pelvic tumors